Recombinant human erythropoietin improves neurological outcomes in very preterm infants

Area of Science:

• Neonatal Medicine
• Neurology
• Pharmacology

Background:

• Very preterm infants face high risks of neurological impairment.
• Early interventions are crucial for improving neurodevelopmental outcomes in neonates.
• Human recombinant erythropoietin (rhEPO) has potential therapeutic benefits in neonatal care.

Purpose of the Study:

• To assess the efficacy of repeated low-dose rhEPO in preventing neurological disability in very preterm infants.
• To evaluate the safety profile of rhEPO treatment in this high-risk population.
• To determine the impact of rhEPO on long-term neurological outcomes at 18 months corrected age.

Main Methods:

• A randomized controlled trial involving 800 infants born at ≤32 weeks gestational age.
• Infants received either rhEPO (500IU/kg) or placebo intravenously within 72 hours of birth, followed by doses every other day for 2 weeks.
• Primary outcome: death or moderate-to-severe neurological disability at 18 months corrected age.

Main Results:

• The rhEPO group showed a significantly lower incidence of death or moderate/severe neurological disability (13.0%) compared to the placebo group (26.9%).
• Neurological disability rates were substantially reduced in the rhEPO group (7.1%) versus placebo (18.8%).
• No excess adverse events were observed in infants treated with rhEPO.

Conclusions:

• Repeated low-dose rhEPO administration is effective in reducing long-term neurological disability in very preterm infants.
• rhEPO treatment appears safe for very preterm infants, with no identified adverse effects.
• This intervention offers a promising strategy to improve neurodevelopmental outcomes in extremely premature neonates.